26
Sep
2024

Pfizer Withdraws Sickle Cell Drug, Arch Hauls in $3B, and BMS Wins Schizophrenia OK

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

BioAge Goes Public, Kailera Piles into GLP-1, and Lilly Bets Big on Indiana
Recursion Scoops up Rival, Servier’s Brain Cancer Win, & Cell Therapy for Solid Tumors
PBMs Feel the Heat, Megarounds Abound, and the XBI Tops 100
Lilly Buys Morphic, Flagship Dreams Big, and Element Challenges Illumina